ClinicalTrials.gg

Program

HS-10504

A development code. Also written as “[¹⁴C]HS-10504” and “HS-10504; midazolam”.

In Hansoh Pharmaceutical Group's pipeline, 4th-gen EGFR. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Hansoh Pharmaceutical Group.

Furthest: phase 3, since Aug 4, 20267 company-led studies, 7 open or runningNext primary completion: Nov 19, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group77 open or runningphase 3since Aug 4, 2026Jun 5, 2024Nov 19, 2026phase 1 · NCT07685041
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-10504 (4th-gen EGFR), phase 3, as of Aug 26, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 5, 2024First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06461156 · 230 planned · China
  2. Jun 1, 2026Phase 1 study in NSCLCNCT07685041 · 24 planned
  3. Jul 20, 20263 phase 1 studiesNCT07770217, NCT07764705, NCT07764692
  4. Aug 4, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungPhase 3 reachedNCT07754123 · 206 planned · China
  5. Sep 11, 2026Phase 1 study in To Compare the Pharmacokinetic (PK) Differences of HS-10504 Between Participants With Hepatic Impairment and Participants With Normal Hepatic FunctionNCT07836504 · 32 planned

Ahead

  1. Nov 19, 2026Primary completion: phase 1 study in NSCLCNCT07685041
  2. Dec 31, 2026Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06461156
  3. Mar 1, 2027Primary completion: phase 1 study in Healthy ParticipantsNCT07764692
  4. Sep 25, 2027Primary completion: phase 1 study in To Compare the Pharmacokinetic (PK) Differences of HS-10504 Between Participants With Hepatic Impairment and Participants With Normal Hepatic FunctionNCT07836504

TargetBeta

“4th-gen EGFR”the company's pipeline, read by Claude · source

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
befotertinibruleBetta Pharmaceuticalsphase 36
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07836504To Compare the Pharmacokinetic (PK) Differences of HS-10504 Between Participants With Hepatic Impairment and Participants With Normal Hepatic Function1Not yet recruitingSep 25, 202732
NCT07754123Carcinoma, Non-Small-Cell Lung · China3RecruitingAug 31, 2028206
NCT07770217Healthy Participants1Not yet recruitingSep 10, 202618
NCT07764705Healthy Subjects1Not yet recruitingSep 30, 20266
NCT07764692Healthy Participants1Not yet recruitingMar 1, 20278
NCT07685041NSCLC1Not yet recruitingNov 19, 202624
NCT06461156Carcinoma, Non-Small-Cell Lung · China1RecruitingDec 31, 2026230

How it is read

Names in the registry

  • “HS-10504”, 5 entries
  • “[¹⁴C]HS-10504”, 1 entry
  • “HS-10504; midazolam”, 1 entry

Codes read as this program: HS10504.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.